Related Experiment Video
Updated: May 30, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
Haemolytic anemia in a patient of Chronic myeloid leukemia: an unrecognized side-effect of Hydroxyurea?
Iffat Jamal1, Shuchi Smita1, Vijayanand Choudhary1
1Department of Pathology (Hematology section), Indira Gandhi Institute of Medical Sciences, Patna, India.
Hydroxyurea (HU) is frequently used in the treatment of various myeloproliferative neoplasms (MPN) where it reduces cell proliferation by impairing DNA synthesis leading to decreased hematopoiesis. Herein we report a case of a 65-year-old female who was diagnosed with Chronic myeloid leukemia and developed severe hemolytic anemia requiring multiple packed red blood cell (RBC) transfusions while being treated with hydroxyurea. The haemolysis persisted until discontinuation of the drug. Common side-effects of HU like macrocytic anemia, leucopenia, and thrombocytopenia are well known but hemolytic anemia is a rare side-effect, not well known with only a handful of cases being described in the scientific literature so far.
Hydroxyurea (HU) is frequently used in the treatment of various myeloproliferative neoplasms (MPN) where it reduces cell proliferation by impairing DNA synthesis leading to decreased hematopoiesis. Herein we report a case of a 65-year-old female who was diagnosed with Chronic myeloid leukemia and developed severe hemolytic anemia requiring multiple packed red blood cell (RBC) transfusions while being treated with hydroxyurea. The haemolysis persisted until discontinuation of the drug. Common side-effects of HU like macrocytic anemia, leucopenia, and thrombocytopenia are well known but hemolytic anemia is a rare side-effect, not well known with only a handful of cases being described in the scientific literature so far.
More Related Videos
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Related Concept Videos
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Antihypertensive Drugs: Action of Diuretics
Regulation of Hematopoietic Stem Cells
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.